LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that it has signed a memorandum of understanding with Bioluz S.A., a privately held French company, for five premix products. The estimated market size of the five products, based on recent IMS data, is approximately $175 million. Premix medications are ready to use intravenous drug products which eliminate compounding steps in the pharmacy or at the point of care.
